Axorus is developing a high acuity artificial retina that utilizes microelectronic technology to restore vision for patients with macular degeneration. This device targets the significant visual impairment caused by the degeneration of retinal cells, aiming to enhance visual function and improve patients' quality of life.
Funding
$420.5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FGFounders
Product
Problem
Patients with advanced macular degeneration or retinitis pigmentosa experience significant vision loss due to damaged photoreceptor cells in the retina. Current treatments offer limited efficacy in restoring functional vision for these individuals.
Solution
Axorus is developing a high-acuity artificial retina that uses photoacoustic technology to stimulate remaining retinal cells and restore vision in patients with damaged photoreceptors. The subretinal implant acts as a substitute for the damaged photoreceptors by converting light into signals that the brain can interpret. This approach aims to provide a higher resolution and more natural visual experience compared to existing artificial vision solutions. The device leverages genetic-free photoacoustic neuromodulation to stimulate cells inside the retina.
Target Audience
The primary target audience includes individuals with advanced macular degeneration or retinitis pigmentosa who have lost photoreceptor function but retain other functional retinal cells.
Features
- Subretinal implant designed to replace damaged photoreceptors in the retina
- Photoacoustic neuromodulation technology for high-precision retinal cell stimulation
- High-acuity design intended to provide enhanced visual resolution
- Suitable for patients with Retinitis Pigmentosa (RP) or advanced dry Age-related Macular Degeneration (AMD)
- Wireless power and data transmission
- Biocompatible materials for long-term implantation